The cluster is small in absolute dollars but directionally consistent, 6 funds all adding while 3 trimming negligibly. D.E. Shaw's quant models finding XERS attractive is a positive signal, but the $2.1M net buy on a micro-cap biotech with recent insider selling suggests moderate conviction, not transformative. Monitor for pipeline catalysts (FDA decisions, trial readouts) that could explain the shared thesis and provide a near-term trigger.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $6.79entry
- T+1 · 5mo ago +1.33%α −0.44% · $6.88
- T+5 · 5mo ago +2.36%α +1.68% · $6.95
- T+20 · 4mo ago +22.83%α +21.05% · $8.34
- T+60 · 2mo ago +24.89%α +21.63% · $8.48
How similar events traded
Executive Summary
Six institutional buyers accumulated $3.5M in XERS shares during 2024-Q3, led by quant hedge fund D.E. Shaw which added $1.6M to its position (now $2.8M), while three asset managers trimmed $82K. The buying is concentrated and net-positive at $2.1M, but absolute dollar amounts are micro-cap scale. Insider selling of $311K over the prior 30 days adds a cautionary note.
Key Financial Metrics
Institutional Positions
Net institutional flow: $2.1M
▲ Buyers (6)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| D.E. Shaw | ADD | +90.1% | $2.8M | $1.6M |
| Legal & General Group | DOUBLED | +1317.9% | $601.0K | $567.0K |
| Corient Private Wealth | ADD | +53.7% | $72.0K | $35.0K |
▼ Sellers (3)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Mariner | TRIM | -54.8% | $151.0K | -$64.5K |
| Metlife Investment Management | TRIM | -28.4% | $186.0K | -$17.2K |
| Lazard Asset Management | TRIM | -40.5% | $1.0K | -$353.00 |
Key Facts
- 6 buyers accumulated $3.5M vs 3 sellers trimmed $82K, net $2.1M into XERS in Q3 2024
- D.E. Shaw (quant/hedge fund) was the dominant buyer: added 467K shares, growing position to $2.8M from $1.2M
- Legal & General Group nearly 14x'd its position (+1318%) to $601K, Corient Private Wealth added 54% to $72K
- Sellers were small-scale trims: Mariner ($65K cut), Metlife ($17K cut), Lazard ($353 cut)
- Prior 30-day insider activity: 3 sells totaling $311K, mild bearish signal at the security level
- Analyst consensus is 85% bullish (5 Strong Buy, 6 Buy, 2 Hold) on this clinical-stage biotech
Financial Impact
Net institutional inflow of approximately $2.1M into XERS stock during Q3 2024, with D.E. Shaw and Legal & General accounting for 93% of buying. Total disclosed institutional positions now ~$3.5M across 6 funds.
Risk Factors
- Absolute dollar amounts are tiny ($3.5M aggregate), may reflect routine rebalancing, not conviction
- 13F data is 45+ days stale; these positions may have been fully unwound since quarter-end
- Recent insider selling ($311K/30d) conflicts with institutional buying signal
- XERS is a clinical-stage biotech with no approved revenue, binary pipeline risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-XERS-2024-Q3 |
Track record
25 reports on XERS
3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +45.52% at T+60 after the Aug 6, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $15.86 settles Dec 8
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $15.20 settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $13.08 settles Dec 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $13.08 settles Dec 4
- Nov 4, 202612d ago 3 Neutral 2/10 Entry $13.08 settles Dec 4
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $10.35 settles Dec 2
- Nov 2, 202614d ago 8-K Neutral 2/10 Entry $10.17 settles Dec 1
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $10.71 settles Nov 30
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $9.77 to $16.52 ▲ +69.09% +70.36% vs SPY
- Oct 2, 20266w ago Insider Cluster Neutral 3/10 Entry $10.13 to $10.71 ▲ +5.73% +8.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers